KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Gross Margin: 2010-2025

Historic Gross Margin for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to 80.91%.

  • Pacira BioSciences' Gross Margin rose 396.00% to 80.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.17%, marking a year-over-year increase of 481.00%. This contributed to the annual value of 75.69% for FY2024, which is 305.00% up from last year.
  • As of Q3 2025, Pacira BioSciences' Gross Margin stood at 80.91%, which was up 4.48% from 77.43% recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Gross Margin peaked at 80.91% during Q3 2025, and registered a low of 63.99% during Q4 2022.
  • Its 3-year average for Gross Margin is 75.53%, with a median of 75.75% in 2023.
  • In the last 5 years, Pacira BioSciences' Gross Margin crashed by 1,150bps in 2022 and then surged by 969bps in 2023.
  • Pacira BioSciences' Gross Margin (Quarterly) stood at 75.50% in 2021, then slumped by 1,150bps to 63.99% in 2022, then skyrocketed by 969bps to 73.69% in 2023, then surged by 501bps to 78.70% in 2024, then skyrocketed by 396bps to 80.91% in 2025.
  • Its Gross Margin stands at 80.91% for Q3 2025, versus 77.43% for Q2 2025 and 79.69% for Q1 2025.